Ki67 expression and prognostic aspects of colorectal cancer

Tjokorda Gde Dharmayuda; Ketut Suega; I Made Bakta; I Made Duwi Sumohadi

doi:10.29332/ijhs.v5n2.1215

Authors

Tjokorda Gde Dharmayuda
cokyuda21@gmail.com
Universitas Udayana, Denpasar, Indonesia
Ketut Suega Universitas Udayana, Denpasar, Indonesia
I Made Bakta Universitas Udayana, Denpasar, Indonesia
I Made Duwi Sumohadi Universitas Udayana, Denpasar, Indonesia

Keywords:

clinical clinical-stage, hemoglobin, histologic grade, immune histochemistry, Ki67, treatment response

Abstract

Colorectal cancer is the growth of malignant cells in the mucosal lining of the large intestine caused by uncontrolled cell growth. Ki67 protein expression found throughout the cell division cycle except in resting cells (G0) can be used as a marker of tumor cell proliferation. Ki67 protein expression was the result of pathological examination with Immuno Histochemistry Staining (IHC) staining from paraffin block of primary tumor biopsy specimens. 38 samples have data on Ki67 level, where the male gender is 28 people (73.7%) and 10 women (26.3%). The age of the patients were 40-64 years, with a mean age of 53 years. Meanwhile, the mean hemoglobin level of the study subjects was 12 g / dl, and the mean CEA level was 77 ng/ml, and a total of 38 samples the median value of Ki67 levels was 80%. There was no correlation between CEA levels and Ki67 expression with p = 0.411. There was no statistical relationship between Ki67 levels with the clinical stage of the tumor (p = 0.316), histopathological grade (p = 0.183) and tumor spread to regional lymph nodes (N) (p = 0.573).

Downloads

Download data is not yet available.

References

Arihiro, K., Oda, M., Ohara, M., Kadoya, T., Osaki, A., Nishisaka, T., ... & Kobayashi, Y. (2016). Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. Japanese journal of clinical oncology, 46(12), 1081-1087.

Ashley M, Benjamin T. (2015). Colorectal cancer in: The Washinton Manual of Oncology Third Edition. 16, 179-187.

Berlin, A., Castro-Mesta, J. F., Rodriguez-Romo, L., Hernandez-Barajas, D., González-Guerrero, J. F., Rodríguez-Fernández, I. A., ... & Vera-Badillo, F. E. (2017, August). Prognostic role of Ki-67 score in localized prostate cancer: a systematic review and meta-analysis. In Urologic Oncology: Seminars and Original Investigations (Vol. 35, No. 8, pp. 499-506). Elsevier. https://doi.org/10.1016/j.urolonc.2017.05.004

Bertucci, F., Finetti, P., Roche, H., Le Doussal, J. M., Marisa, L., Martin, A. L., ... & Pénault-Llorca, F. (2013). Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. Annals of oncology, 24(3), 625-632. https://doi.org/10.1093/annonc/mds510

Brown, D. C., & Gatter, K. C. (2002). Ki67 protein: the immaculate deception?. Histopathology, 40(1), 2-11.

Buskermolen, M., Cenin, D. R., Helsingen, L. M., Guyatt, G., Vandvik, P. O., Haug, U., ... & Lansdorp-Vogelaar, I. (2019). Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. bmj, 367.

Clay, V., Papaxoinis, G., Sanderson, B., Valle, J. W., Howell, M., Lamarca, A., ... & Mansoor, W. (2017). Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. Clinical and Translational Oncology, 19(5), 579-586. https://doi.org/10.1007/s12094-016-1568-z

Denkert, C., Budczies, J., von Minckwitz, G., Wienert, S., Loibl, S., & Klauschen, F. (2015). Strategies for developing Ki67 as a useful biomarker in breast cancer. The Breast, 24, S67-S72. https://doi.org/10.1016/j.breast.2015.07.017

Duchrow, M., Schlüter, C., Wohlenberg, C., Flad, H. D., & Gerdes, J. (1996). Molecular characterization of the gene locus of the human cell proliferation?associated nuclear protein defined by monoclonal antibody Ki?67. Cell proliferation, 29(1), 1-12. https://doi.org/10.1046/j.1365-2184.1996.d01-2.x

Fluge, Ø., Gravdal, K., Carlsen, E., Vonen, B., Kjellevold, K., Refsum, S., ... & Dahl, O. (2009). Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British journal of cancer, 101(8), 1282-1289. https://doi.org/10.1038/sj.bjc.6605333

Gil, R. S., & Vagnarelli, P. (2018). Ki-67: more hidden behind a ‘classic proliferation marker’. Trends in biochemical sciences, 43(10), 747-748. https://doi.org/10.1016/j.tibs.2018.08.004

Gonzalez-Moles, M. A., Ruiz-Avila, I., Gil-Montoya, J. A., Esteban, F., & Bravo, M. (2010). Analysis of Ki-67 expression in oral squamous cell carcinoma: why Ki-67 is not a prognostic indicator. Oral oncology, 46(7), 525-530. https://doi.org/10.1016/j.oraloncology.2010.03.020

Hayashi, H., Beppu, T., Sakamoto, Y., Miyamoto, Y., Yokoyama, N., Higashi, T., ... & Baba, H. (2015). Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases. American journal of cancer research, 5(3), 1225.

Heidari, Z., Mahmoudzadeh-Sagheb, H., Jahantigh, M., & Charkhat Gorgich, E. A. (2017). Immunohistochemical expression of Ki67 and HER2 in colorectal cancer compared to adenomatous and normal samples. International Journal of Cancer Management, 10(11).

Helsingen, L. M., Vandvik, P. O., Jodal, H. C., Agoritsas, T., Lytvyn, L., Anderson, J. C., ... & Guyatt, G. (2019). Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. Bmj, 367.

Ivanecz, A., Kavalar, R., Palfy, M., Pivec, V., Sremec, M., Horvat, M., & Potr?, S. (2014). Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases. HPB, 16(3), 235-242. https://doi.org/10.1111/hpb.12089

Kausch, I., & Böhle, A. (2002). Molecular aspects of bladder cancer: III. Prognostic markers of bladder cancer. European urology, 41(1), 15-29. https://doi.org/10.1016/S0302-2838(01)00007-0

Konstantinos N, Philip S, Dimitrios M, Neoklis K. (2013). Marker of proliferation Ki-67. Gene Section Review, Atlas of genetics and cytogenetics in oncology and haematology. 19(2), 105-116.

Li, P., Xiao, Z. T., Braciak, T. A., Ou, Q. J., Chen, G., & Oduncu, F. S. (2016). Association between Ki67 index and clinicopathological features in colorectal cancer. Oncology research and treatment, 39(11), 696-702.

Luo, Z. W., Zhu, M. G., Zhang, Z. Q., Ye, F. J., Huang, W. H., & Luo, X. Z. (2019). Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis. BMC cancer, 19(1), 1-13.

Marino, M. T., Grilli, A., Baricordi, C., Manara, M. C., Ventura, S., Pinca, R. S., ... & Scotlandi, K. (2014). Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression. Annals of oncology, 25(10), 2080-2086. https://doi.org/10.1093/annonc/mdu249

Melling, N., Kowitz, C. M., Simon, R., Bokemeyer, C., Terracciano, L., Sauter, G., ... & Marx, A. H. (2016). High Ki67 expression is an independent good prognostic marker in colorectal cancer. Journal of clinical pathology, 69(3), 209-214.

Murdani Abdullah (2015). Tumor kolorektal. Buku Ajar Ilmu Penyakit Dalam, 2(4), 373-380.

Nishimukai, A., Yagi, T., Yanai, A., Miyagawa, Y., Enomoto, Y., Murase, K., ... & Miyoshi, Y. (2015). High Ki-67 expression and low progesterone receptor expression could independently lead to a worse prognosis for postmenopausal patients with estrogen receptor-positive and HER2-negative breast cancer. Clinical breast cancer, 15(3), 204-211. https://doi.org/10.1016/j.clbc.2014.12.007

Penault-Llorca, F., & Radosevic-Robin, N. (2017). Ki67 assessment in breast cancer: an update. Pathology, 49(2), 166-171. https://doi.org/10.1016/j.pathol.2016.11.006 Arihiro K, Oda M, Ohara M, Kadoya T, Osaki A, Nishisaka T, Shiroma N and Kobayashi Y: Comparison of visual assessment and image analysis in the evaluation of Ki?67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. Jpn J Clin Oncol 2016; 46: 1081?1087.

Raper, J. & Hung, K.E. (2013). molecular mechanisms of colorectal carsinogenesis, in: K.M. Haigis (ed), molecular Pathogenesis of Colorectal cancer. 2, 25-54.

Roper, J., & Hung, K. E. (2013). Molecular mechanisms of colorectal carcinogenesis. In Molecular Pathogenesis of Colorectal Cancer (pp. 25-65). Springer, New York, NY.

Salminen, E., Palmu, S., Vahlberg, T., Roberts, P. J., & Söderström, K. O. (2005). Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World journal of gastroenterology: WJG, 11(21), 3245..

Salminen, P., Paajanen, H., Rautio, T., Nordström, P., Aarnio, M., Rantanen, T., ... & Grönroos, J. M. (2015). Antibiotic therapy vs appendectomy for treatment of uncomplicated acute appendicitis: the APPAC randomized clinical trial. Jama, 313(23), 2340-2348.

Sysel, A. M., Valli, V. E., & Bauer, J. A. (2015). Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissues. Oncotarget, 6(4), 2331.

Tian, Y., Ma, Z., Chen, Z., Li, M., Wu, Z., Hong, M., ... & Wang, Z. (2016). Clinicopathological and prognostic value of Ki-67 expression in bladder cancer: a systematic review and meta-analysis. PloS one, 11(7), e0158891.

Tong, G., Zhang, G., Liu, J., Zheng, Z., Chen, Y., Niu, P., & Xu, X. (2020). Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC 8 stratification. Oncology reports, 43(4), 1187-1198.

Weber, J. C., Nakano, H., Bachellier, P., Oussoultzoglou, E., Inoue, K., Shimura, H., ... & Jaeck, D. (2001). Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases?. The American journal of surgery, 182(1), 81-88. https://doi.org/10.1016/S0002-9610(01)00656-0

Xi, H. Q., & Zhao, P. (2011). Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. Journal of clinical pathology, 64(6), 498-503.

Xiong, D. D., Lin, X. G., He, R. Q., Pan, D. H., Luo, Y. H., Dang, Y. W., ... & Gan, T. Q. (2017). Ki67/MIB-1 predicts better prognoses in colorectal cancer patients received both surgery and adjuvant radio-chemotherapy: a meta-analysis of 30 studies. Int J Clin Exp Med, 10(2), 1788-804.

Yan, J. A., & Chou, M. Y. (2010). Oxidation functional groups on graphene: Structural and electronic properties. Physical review B, 82(12), 125403.Arihiro K, Oda M, Ohara M, Kadoya T, Osaki A, Nishisaka T, Shiroma N and Kobayashi Y: Comparison of visual assessment and image analysis in the evaluation of Ki?67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. Jpn J Clin Oncol 2016; 46: 1081?1087.